JPMorgan initiates coverage on Definium Therapeutics at Overweight

JPMorgan initiated coverage of Definium Therapeutics (DFTX) with an Overweight rating and an $84 price target, citing the development of lead asset DT120 ODT for various neuropsychiatric disorders. The note characterizes DT120 ODT as a psychedelic drug with potential to shift the neuropsychiatry treatment paradigm and calls it “intriguing pipeline-in-a-product potential.”